| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Total revenues | 12,462 | |||
| Cost of product sales | 660 | |||
| Research and development | 29 | |||
| Selling and marketing | 5,210 | |||
| General and administrative | 6,752 | |||
| Total operating expenses | 12,651 | |||
| (loss)/income from operations | -189 | |||
| Unrealized foreign exchange gain/(loss) | -3 | |||
| Amortization expense | 12 | |||
| Interest income | 152 | |||
| Interest expense | 586 | |||
| Total other expense | -449 | |||
| Net (loss)/income | -638 | |||
| Earnings per share, basic | -0.02 | |||
| Earnings per share, diluted | -0.02 | |||
| Weighted average number of shares outstanding, basic | 27,889,000 | |||
| Weighted average number of shares outstanding, diluted | 27,889,000 | |||
FENNEC PHARMACEUTICALS INC. (FENCF)
FENNEC PHARMACEUTICALS INC. (FENCF)